NCT04652960 2026-04-13Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary SyndromeNational Cancer Institute (NCI)Phase 1 Active not recruiting38 enrolled
NCT03534323 2026-03-23Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RSDana-Farber Cancer InstitutePhase 1/2 Active not recruiting55 enrolled 14 charts